Cargando…

A novel (11)C-labeled thymidine analog, [(11)C]AZT, for tumor imaging by positron emission tomography

BACKGROUND: Nucleoside analogs labeled with positrons, such as (11)C and (18)F, are considered valuable in visualizing the proliferative activity of tumor cells in vivo using positron emission tomography (PET). We recently developed the (11)C-labeled thymidine analogs [(11)C]zidovudine ([(11)C]AZT)...

Descripción completa

Detalles Bibliográficos
Autores principales: Tahara, Tsuyoshi, Zhang, Zhouen, Ohno, Masahiro, Hirao, Yukako, Hosaka, Nami, Doi, Hisashi, Suzuki, Masaaki, Onoe, Hirotaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4597405/
https://www.ncbi.nlm.nih.gov/pubmed/26337804
http://dx.doi.org/10.1186/s13550-015-0124-0
_version_ 1782393917906354176
author Tahara, Tsuyoshi
Zhang, Zhouen
Ohno, Masahiro
Hirao, Yukako
Hosaka, Nami
Doi, Hisashi
Suzuki, Masaaki
Onoe, Hirotaka
author_facet Tahara, Tsuyoshi
Zhang, Zhouen
Ohno, Masahiro
Hirao, Yukako
Hosaka, Nami
Doi, Hisashi
Suzuki, Masaaki
Onoe, Hirotaka
author_sort Tahara, Tsuyoshi
collection PubMed
description BACKGROUND: Nucleoside analogs labeled with positrons, such as (11)C and (18)F, are considered valuable in visualizing the proliferative activity of tumor cells in vivo using positron emission tomography (PET). We recently developed the (11)C-labeled thymidine analogs [(11)C]zidovudine ([(11)C]AZT) and [(11)C]stavudine ([(11)C]d4T) via the Pd(0)-Cu(I) co-mediated rapid C–C coupling reaction. In this study, to examine whether [(11)C]AZT and [(11)C]d4T might be useful for visualization of tumors in vivo, we performed PET imaging, tissue distribution studies, and metabolite analysis in tumor-bearing mice. METHODS: Mice bearing tumors (rat glioma C6 and human cervical adenocarcinoma HeLa cells) were injected with 50 MBq of [(11)C]AZT or [(11)C]d4T, and PET was performed immediately thereafter. After PET imaging, the radioactivity in several tissues, including tumor tissues, was measured using a γ-counter. In addition, radioactive metabolites in plasma, bile, intestinal contents, and tumor were analyzed using thin layer chromatography (TLC). Cellular uptake of [(11)C]AZT in C6 was measured in the presence or absence of non-labeled thymidine (0.1 mM). RESULTS: In PET studies, C6 and HeLa tumors in mice were clearly visualized using [(11)C]AZT. Time-activity curves using [(11)C]AZT showed that the accumulation of radioactivity in tumors plateaued at 10 min after injection and persisted for 60 min, while most of the radioactivity in other tissues was rapidly excreted into the urine. In various tissues of the body, tumor tissue showed the highest radioactivity at 80 min after injection (five to six times higher uptake than that of blood). Compared with tumor tissue, uptake was lower in other proliferative tissues such as the spleen, intestine, and bone marrow, resulting in a high tumor-to-bone marrow ratio. Cellular uptake of [(11)C]AZT in C6 cells was completely blocked by the application of thymidine, strongly indicating the specific involvement of nucleoside transporters. In contrast, the time-activity curve of [(11)C]d4T in the tumor showed transient and rapid excretion with almost no obvious tumor tissue accumulation. CONCLUSIONS: Tumors can be detected by PET using [(11)C]AZT; therefore, [(11)C]AZT could be useful as a novel PET tracer for tumor imaging in vivo. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13550-015-0124-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4597405
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-45974052015-10-13 A novel (11)C-labeled thymidine analog, [(11)C]AZT, for tumor imaging by positron emission tomography Tahara, Tsuyoshi Zhang, Zhouen Ohno, Masahiro Hirao, Yukako Hosaka, Nami Doi, Hisashi Suzuki, Masaaki Onoe, Hirotaka EJNMMI Res Research Article BACKGROUND: Nucleoside analogs labeled with positrons, such as (11)C and (18)F, are considered valuable in visualizing the proliferative activity of tumor cells in vivo using positron emission tomography (PET). We recently developed the (11)C-labeled thymidine analogs [(11)C]zidovudine ([(11)C]AZT) and [(11)C]stavudine ([(11)C]d4T) via the Pd(0)-Cu(I) co-mediated rapid C–C coupling reaction. In this study, to examine whether [(11)C]AZT and [(11)C]d4T might be useful for visualization of tumors in vivo, we performed PET imaging, tissue distribution studies, and metabolite analysis in tumor-bearing mice. METHODS: Mice bearing tumors (rat glioma C6 and human cervical adenocarcinoma HeLa cells) were injected with 50 MBq of [(11)C]AZT or [(11)C]d4T, and PET was performed immediately thereafter. After PET imaging, the radioactivity in several tissues, including tumor tissues, was measured using a γ-counter. In addition, radioactive metabolites in plasma, bile, intestinal contents, and tumor were analyzed using thin layer chromatography (TLC). Cellular uptake of [(11)C]AZT in C6 was measured in the presence or absence of non-labeled thymidine (0.1 mM). RESULTS: In PET studies, C6 and HeLa tumors in mice were clearly visualized using [(11)C]AZT. Time-activity curves using [(11)C]AZT showed that the accumulation of radioactivity in tumors plateaued at 10 min after injection and persisted for 60 min, while most of the radioactivity in other tissues was rapidly excreted into the urine. In various tissues of the body, tumor tissue showed the highest radioactivity at 80 min after injection (five to six times higher uptake than that of blood). Compared with tumor tissue, uptake was lower in other proliferative tissues such as the spleen, intestine, and bone marrow, resulting in a high tumor-to-bone marrow ratio. Cellular uptake of [(11)C]AZT in C6 cells was completely blocked by the application of thymidine, strongly indicating the specific involvement of nucleoside transporters. In contrast, the time-activity curve of [(11)C]d4T in the tumor showed transient and rapid excretion with almost no obvious tumor tissue accumulation. CONCLUSIONS: Tumors can be detected by PET using [(11)C]AZT; therefore, [(11)C]AZT could be useful as a novel PET tracer for tumor imaging in vivo. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13550-015-0124-0) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2015-09-04 /pmc/articles/PMC4597405/ /pubmed/26337804 http://dx.doi.org/10.1186/s13550-015-0124-0 Text en © Tahara et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Research Article
Tahara, Tsuyoshi
Zhang, Zhouen
Ohno, Masahiro
Hirao, Yukako
Hosaka, Nami
Doi, Hisashi
Suzuki, Masaaki
Onoe, Hirotaka
A novel (11)C-labeled thymidine analog, [(11)C]AZT, for tumor imaging by positron emission tomography
title A novel (11)C-labeled thymidine analog, [(11)C]AZT, for tumor imaging by positron emission tomography
title_full A novel (11)C-labeled thymidine analog, [(11)C]AZT, for tumor imaging by positron emission tomography
title_fullStr A novel (11)C-labeled thymidine analog, [(11)C]AZT, for tumor imaging by positron emission tomography
title_full_unstemmed A novel (11)C-labeled thymidine analog, [(11)C]AZT, for tumor imaging by positron emission tomography
title_short A novel (11)C-labeled thymidine analog, [(11)C]AZT, for tumor imaging by positron emission tomography
title_sort novel (11)c-labeled thymidine analog, [(11)c]azt, for tumor imaging by positron emission tomography
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4597405/
https://www.ncbi.nlm.nih.gov/pubmed/26337804
http://dx.doi.org/10.1186/s13550-015-0124-0
work_keys_str_mv AT taharatsuyoshi anovel11clabeledthymidineanalog11caztfortumorimagingbypositronemissiontomography
AT zhangzhouen anovel11clabeledthymidineanalog11caztfortumorimagingbypositronemissiontomography
AT ohnomasahiro anovel11clabeledthymidineanalog11caztfortumorimagingbypositronemissiontomography
AT hiraoyukako anovel11clabeledthymidineanalog11caztfortumorimagingbypositronemissiontomography
AT hosakanami anovel11clabeledthymidineanalog11caztfortumorimagingbypositronemissiontomography
AT doihisashi anovel11clabeledthymidineanalog11caztfortumorimagingbypositronemissiontomography
AT suzukimasaaki anovel11clabeledthymidineanalog11caztfortumorimagingbypositronemissiontomography
AT onoehirotaka anovel11clabeledthymidineanalog11caztfortumorimagingbypositronemissiontomography
AT taharatsuyoshi novel11clabeledthymidineanalog11caztfortumorimagingbypositronemissiontomography
AT zhangzhouen novel11clabeledthymidineanalog11caztfortumorimagingbypositronemissiontomography
AT ohnomasahiro novel11clabeledthymidineanalog11caztfortumorimagingbypositronemissiontomography
AT hiraoyukako novel11clabeledthymidineanalog11caztfortumorimagingbypositronemissiontomography
AT hosakanami novel11clabeledthymidineanalog11caztfortumorimagingbypositronemissiontomography
AT doihisashi novel11clabeledthymidineanalog11caztfortumorimagingbypositronemissiontomography
AT suzukimasaaki novel11clabeledthymidineanalog11caztfortumorimagingbypositronemissiontomography
AT onoehirotaka novel11clabeledthymidineanalog11caztfortumorimagingbypositronemissiontomography